The Initiative on Public-Private Partnerships for Health commissioned researchers from the Institute for Global Health (IGH) at the University of California, San Francisco, to evaluate the contributions that private industry has made - both compensated and "in kind" - to public-private partnerships (PPPs) involved in the development of new treatments for diseases prevalent in the developing world. This paper presents the findings of this study and makes recommendations for future collaboration with industry.